BioSpace News Archive

Financing will support Phase 3 trial of FCR001 for living donor kidney transplant patients and additional Phase 2 studies in high-need indications

FCR001 established durable immune tolerance in 70% of patients

Danaher Corporation announced results for the first quarter 2019.

Phyton Biotech and AqVida are pleased to announce today that they have received European approval from the EDQM for AqVida’s paclitaxel injectable FDF.

Acorda Therapeutics, Inc. will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET.

Designation based on positive primary analysis of pivotal study, N-MOmentum

Mocha OB, a group comprised of over 500 female OB/GYNs, OB trained Family Practice Physicians and Cardiologists of color have been working all week in various activities and have issued the following statement regarding Black Maternal Health week

Moleculin Biotech, Inc., announced that the U.S. Food and Drug Administration has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia.

Hoth Therapeutics, Inc.(NASDAQ: HOTH), announced today its Chief Executive Officer Mr. Robb Knie will be joined by other members of the management team to ring the NASDAQ Closing Bell on Monday, April 22, 2019

HitGen Inc., announced today that it has achieved a milestone in its discovery alliance with Merck & Co. Inc., Kenilworth NJ, USA, known as MSD outside the United States and Canada. The milestone was for the identification of candidates meeting pre-defined criteria, representing the 3rd discovery program between the two companies for which HitGen has achieved this milestone.